We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Intellectual Property Office offers different methods of accelerating the processing of your patent application.
We help people, businesses and the UK economy by promoting competitive markets and tackling unfair behaviour. CMA is a non-ministerial department.
Data sources of numbers relating to the coronavirus pandemic in the UK.
Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.
Apply for a higher education course, track your application and accept or reject your offers.
Information on enhancing communications resilience and how we work with telecommunication service providers to manage the risk of disruption to public networks.
The Accelerated Access Review aims to speed up access to innovative drugs, devices and diagnostics for NHS patients.
Information on how UK businesses can control risks when operating in Indonesia.
Why it's important to evaluate digital health products that have been developed rapidly and how to choose evaluation methods in these circumstances.
This toolkit is for Innovation Passport holders following the Innovative Licensing and Access Pathway (ILAP) and provides activities to support the design and development of medicines.
FCDO travel advice for Brazil. Includes safety and security, insurance, entry requirements and legal differences.
Compare different evaluation approaches and choose an appropriate method.
This guide explains how impacts on noise should be incorporated into a cost benefit analysis.
The MHRA is part of the Access Consortium along with the Therapeutic Goods Administration, Health Canada, Health Sciences Authority of Singapore and Swissmedic.
Reports relating to the coronavirus (COVID-19) testing initiative evaluation programme.
Guidance on the planning for mineral extraction in plan making and the application process.
How marketing authorisation holders should inform MHRA of a signal or an ADR to a medicine.
Sign up for upcoming webinars to learn more about UK transition.
Urgent safety updates arising from pharmacovigilance data, including reported adverse events, for veterinary medicines authorised in the UK.
Find out how new Brexit rules apply to things like travelling, working, studying and doing business with Europe in or with EU countries.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.